CA3020344A1 - Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease - Google Patents

Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease Download PDF

Info

Publication number
CA3020344A1
CA3020344A1 CA3020344A CA3020344A CA3020344A1 CA 3020344 A1 CA3020344 A1 CA 3020344A1 CA 3020344 A CA3020344 A CA 3020344A CA 3020344 A CA3020344 A CA 3020344A CA 3020344 A1 CA3020344 A1 CA 3020344A1
Authority
CA
Canada
Prior art keywords
tdp
seq
mitochondrial
mice
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3020344A
Other languages
English (en)
French (fr)
Inventor
Xinglong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of CA3020344A1 publication Critical patent/CA3020344A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3020344A 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease Abandoned CA3020344A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662319580P 2016-04-07 2016-04-07
US62/319,580 2016-04-07
US201662328484P 2016-04-27 2016-04-27
US62/328,484 2016-04-27
PCT/US2017/026675 WO2017177178A1 (en) 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
CA3020344A1 true CA3020344A1 (en) 2017-10-12

Family

ID=60000683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020344A Abandoned CA3020344A1 (en) 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease

Country Status (9)

Country Link
US (3) US11124553B2 (enExample)
EP (1) EP3440094B1 (enExample)
JP (1) JP2019513752A (enExample)
KR (1) KR20180132807A (enExample)
CN (1) CN109563130A (enExample)
AU (1) AU2017248353A1 (enExample)
CA (1) CA3020344A1 (enExample)
SG (1) SG11201808829VA (enExample)
WO (1) WO2017177178A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645557B1 (en) * 2017-06-28 2024-10-23 The Cleveland Clinic Foundation Treatment of nervous system injury and neurodegenerative disorders and related conditions
CN113683703B (zh) * 2020-05-18 2023-08-15 中国人民解放军陆军军医大学第二附属医院 一种hTERT靶向物及其用途
WO2021247893A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Bicyclic heteroaromatic amide compounds and uses thereof
WO2022015997A2 (en) * 2020-07-15 2022-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of tdp-43 activity and uses thereof
CN114057858B (zh) * 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
KR102488166B1 (ko) 2020-09-24 2023-01-13 재단법인대구경북과학기술원 Ｈｄａｃ６의 ｔｄｐ－４３ 단백질병증 예방 또는 치료제로서의 용도
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
CN113450336B (zh) * 2021-07-01 2022-10-25 维柯基科技(上海)有限公司 一种多孔荧光微阵列图像的处理方法、装置、计算机设备及计算机可读存储介质
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
KR20240133923A (ko) * 2023-02-28 2024-09-05 (주)케어젠 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물
KR102859015B1 (ko) 2023-07-20 2025-09-12 충북대학교 산학협력단 ｃ­Ａｂｌ에 의한 ＴＤＰ­４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途
KR20260012942A (ko) * 2024-07-19 2026-01-27 재단법인대구경북과학기술원 디히드로코스투스 락톤을 유효성분으로 포함하는 ｆｕｓ 또는 ｔｄｐ­４３ 관련 질환의 예방 또는 치료용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
GB9723824D0 (en) * 1997-11-11 1998-01-07 Actinova Ltd Cytostatic agents
US6841535B2 (en) 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use
US20040229837A1 (en) * 2003-05-15 2004-11-18 Yijuang Chern Treatment of neurodegenerative diseases
US20070014803A1 (en) * 2005-07-01 2007-01-18 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of viral and bacterial infections
ES2526060T3 (es) 2006-12-06 2015-01-05 Thomas Jefferson University Péptido y tratamiento para la infección del VIH-1
WO2009099941A2 (en) 2008-02-01 2009-08-13 Washington University In St. Louis Sequences associated with tdp-43 proteinopathies and methods of using the same
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US9926353B2 (en) * 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US20150045248A1 (en) 2012-02-28 2015-02-12 National University Corporation Tokyo University Of Agriculture And Technology Method for identifying disease associated with abundance of tdp-43 in cell
US9017672B2 (en) * 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
WO2013192298A1 (en) * 2012-06-22 2013-12-27 The Scripps Research Institute Apoptosis biomarkers
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)

Also Published As

Publication number Publication date
EP3440094A4 (en) 2019-03-20
EP3440094A1 (en) 2019-02-13
WO2017177178A1 (en) 2017-10-12
AU2017248353A1 (en) 2018-10-25
SG11201808829VA (en) 2018-11-29
US20190211070A1 (en) 2019-07-11
US20220220173A1 (en) 2022-07-14
US20260116935A1 (en) 2026-04-30
KR20180132807A (ko) 2018-12-12
CN109563130A (zh) 2019-04-02
US12129285B2 (en) 2024-10-29
EP3440094B1 (en) 2021-02-17
US11124553B2 (en) 2021-09-21
JP2019513752A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
US12129285B2 (en) TDP-43 mitochondrial localization inhibitor for the treatment of neurogenerative disease
JP6203215B2 (ja) プロミニン−１ペプチド断片およびその使用
JP2018521014A (ja) ミスフォールドタンパク質の分解のための組成物及び方法
JP2019501210A (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
AU2024266863A1 (en) Compositions and methods for treating myelin disorders
US20180327458A1 (en) Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
US11129866B2 (en) Inhibitors of valosin-containing protein and methods of use
US10258672B2 (en) Compositions and methods of treating root avulsion injury
US12403184B2 (en) Compositions and methods for treating neurodegenerative disroders
JP2020524132A (ja) アルツハイマー病を治療するための組成物および方法
EP1799272A2 (en) Promotion of cell migration and axon regeneration in the cns
US11136362B2 (en) Peptide modulators of specific calcineurin protein-protein interactions
EP2522359A1 (en) Compounds with thioredoxin-like fold domain for the treatment of degenerative disorders
HK40021220B (en) Compositions and methods for treating myelin disorders
HK40021220A (en) Compositions and methods for treating myelin disorders

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221007